Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027

What happened

Compass Pathways said it expects to complete its New Drug Application for COMP360, its treatment for treatment-resistant depression, within two weeks. The company is preparing for a potential commercial launch in the first half of 2027.

Confirmed

Global impact / market context

Finishing the application moves COMP360 closer to regulatory review, which could let Compass sell the treatment and earn revenue. A first-half 2027 launch target gives investors a timeline to judge spending against future sales, while approval remains uncertain and could still delay or block that revenue.

Analyst inference

COMP360 met its main goals in two late-stage trials with over 1,000 patients, and follow-up data showed benefits lasting up to a year. Those results support the filing case, but investors still face the risk that review or launch timing slips before any sales occur.

Analyst inference

What to watch

1. Watch whether Compass completes its New Drug Application submission for COMP360 within the stated two weeks, since that filing starts the formal regulatory review process. Confirmed
2. Watch for updates on the first-half 2027 launch plan, including completion of sales team hiring, which the company said is underway to prepare for a potential commercial launch. Proposed
3. Watch whether regulators approve COMP360 and how quickly, because a slow or negative review would push back revenue and leave Compass carrying launch costs without sales. Analyst inference

Evidence

• stocktwits.com